Vandetanib

凡德他尼

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameVandetanib
Drug Alias Namevandetanibum凡他尼布Zictifa范得他尼Zactima +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVascular endothelial growth factor receptor 2 inhibitorsTyrosine-protein kinase receptor RET inhibitorsEGFR T790M inhibitors
TargetsVascular endothelial growth factor receptor 2Tyrosine-protein kinase receptor RETEGFR T790M
Therapy Area/IndicationsMedullary thyroid cancer (MTC)Metastatic breast cancerSolid tumours +[59] 
Global Approved IndicationsMedullary thyroid cancer (MTC)Thyroid NeoplasmsCarcinoma, Neuroendocrine
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2011/04/06
Country/TerritoryCzechiaBelgiumBulgaria +[48] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesEsteve Healthcare SLAstrazeneca Pharmaceutical Co LtdSanofi +[6] 
Inactive CompaniesDana-Farber Cancer InstituteNational Institutes Of Health Clinical Center (Cc)Roswell Park Cancer Institute +[17] 
Active IndicationsMedullary thyroid cancer (MTC)Carcinoma, Non-Small-Cell LungLung Neoplasms +[5] 
Inactive IndicationsMetastatic breast cancerSolid tumoursAmpullary Carcinoma +[54] 

Other Information

ATC CodeL01EX04
Related LinksWikipediaDrugBankKEGG